checkAd

DGAP-Adhoc Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

Nachrichtenquelle: EQS Group AG
19.03.2021, 19:22  |  125   |   |   

DGAP-Ad-hoc: Heidelberg Pharma AG / Key word(s): Financing
Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

19-March-2021 / 19:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement - Inside information pursuant to Article 17 MAR

Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

Ladenburg, Germany, 19 March 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini). dievini will provide the Company with up to EUR 30 million. The detailed form of the financing will be decided by the management and supervisory boards of Heidelberg Pharma as well as dievini at a later date.

The financing commitment will enable Heidelberg Pharma to advance its business activities, in particular to conduct the clinical Phase I/IIa of the HDP-101 and to further develop the candidates HDP-102 und HDP-103. Based on the current planning, the Company's cash reach is secured until mid-2022.

 


Information and Explanation of the Issuer to this News:

About Heidelberg Pharma

Heidelberg Pharma AG is an oncology company and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the Company's own therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

Contact
Heidelberg Pharma AG
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Seite 1 von 3
Heidelberg Pharma Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

Diskussion: Heidelberg Pharma AG


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-Adhoc Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini DGAP-Ad-hoc: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini 19-March-2021 / 19:22 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

COMMUNITY

ZeitTitel
09.04.21
17.06.20